ES2060685T3 - Medicamento con contenido de azelastina con liberacion controlada del principio activo. - Google Patents
Medicamento con contenido de azelastina con liberacion controlada del principio activo.Info
- Publication number
- ES2060685T3 ES2060685T3 ES89106685T ES89106685T ES2060685T3 ES 2060685 T3 ES2060685 T3 ES 2060685T3 ES 89106685 T ES89106685 T ES 89106685T ES 89106685 T ES89106685 T ES 89106685T ES 2060685 T3 ES2060685 T3 ES 2060685T3
- Authority
- ES
- Spain
- Prior art keywords
- active substance
- controlled release
- azelastin
- medication
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Rotary Pumps (AREA)
- Switches With Compound Operations (AREA)
- Polyurethanes Or Polyureas (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
MEDICAMENTOS CON ACELASTINA CON CESION CONTROLADA DE SUSTANCIAS ACTIVAS CON UTILIZACION DE UN COMPONENTE DE RETARDO, HABIENDO POR CADA PARTE DE PESO DE ACELASTINA (REFERIDO A LA BASE) 0,001 A 800 PARTES DE COMPONENTE DE RETARDO, PUDIENDO ESTAR LA ACELASTINA PRESENTE TAMBIEN EN FORMA DE SALES FISIOLOGICAMENTE INOFENSIVAS. LA VELOCIDAD DE LIBERACION DE ACELASTINA ESTA ENTRE 0,05 Y 5 MG POR HORA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3813244 | 1988-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2060685T3 true ES2060685T3 (es) | 1994-12-01 |
Family
ID=6352451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES89106685T Expired - Lifetime ES2060685T3 (es) | 1988-04-20 | 1989-04-14 | Medicamento con contenido de azelastina con liberacion controlada del principio activo. |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0338444B1 (es) |
JP (1) | JP2950845B2 (es) |
AT (1) | ATE97572T1 (es) |
AU (1) | AU3318389A (es) |
CA (1) | CA1325976C (es) |
DE (1) | DE58906232D1 (es) |
DK (1) | DK172235B1 (es) |
ES (1) | ES2060685T3 (es) |
FI (1) | FI891865A (es) |
HK (1) | HK134494A (es) |
HU (1) | HU202403B (es) |
IE (1) | IE62778B1 (es) |
MC (1) | MC2025A1 (es) |
PT (1) | PT90308B (es) |
ZA (1) | ZA892877B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9003903D0 (sv) * | 1990-12-07 | 1990-12-07 | Astra Ab | New pharmaceutical formulations |
DE4207234A1 (de) * | 1992-03-07 | 1993-09-09 | Asta Medica Ag | Neue aminocarbonsaeure-derivate mit antiallergischer/antiasthmatischer wirkung und verfahren zu deren herstellung |
JPH0710747A (ja) * | 1993-04-28 | 1995-01-13 | Takeda Chem Ind Ltd | 固形製剤およびその製造方法 |
GB9514842D0 (en) * | 1995-07-20 | 1995-09-20 | Smithkline Beecham Plc | Novel formulation |
JP4138910B2 (ja) | 1997-07-02 | 2008-08-27 | 帝國製薬株式会社 | 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤 |
UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
PL205109B1 (pl) | 1998-11-02 | 2010-03-31 | Elan Pharma Int Ltd | Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie |
IL149352A0 (en) | 1999-10-29 | 2002-11-10 | Euro Celtique Sa | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
EP2295042A1 (en) | 2000-10-30 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
EP1396263A1 (en) * | 2002-08-09 | 2004-03-10 | Warner-Lambert Company | Film coating for tablets and caplets |
CA2510319A1 (en) * | 2002-12-20 | 2004-07-15 | Thomas J. Smith | High pressure compaction for pharmaceutical formulations |
SI2522365T1 (sl) * | 2004-11-24 | 2017-02-28 | Meda Pharmaceuticals Inc. | Sestavki, ki obsegajo azelastin, in postopki njihove uporabe |
US9987233B2 (en) | 2013-03-21 | 2018-06-05 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
SG11201803156TA (en) | 2015-10-27 | 2018-05-30 | Eupraxia Pharmaceuticals Inc | Sustained release formulations of local anesthetics |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0174464B1 (de) * | 1984-09-14 | 1990-01-03 | ASTA Pharma AG | Substituierte Benzylphthalazinon-Derivate |
-
1989
- 1989-04-11 MC MC892044A patent/MC2025A1/xx unknown
- 1989-04-14 DE DE89106685T patent/DE58906232D1/de not_active Expired - Lifetime
- 1989-04-14 ES ES89106685T patent/ES2060685T3/es not_active Expired - Lifetime
- 1989-04-14 EP EP89106685A patent/EP0338444B1/de not_active Expired - Lifetime
- 1989-04-14 AT AT89106685T patent/ATE97572T1/de not_active IP Right Cessation
- 1989-04-19 PT PT90308A patent/PT90308B/pt not_active IP Right Cessation
- 1989-04-19 HU HU891912A patent/HU202403B/hu not_active IP Right Cessation
- 1989-04-19 FI FI891865A patent/FI891865A/fi not_active Application Discontinuation
- 1989-04-19 ZA ZA892877A patent/ZA892877B/xx unknown
- 1989-04-19 IE IE126389A patent/IE62778B1/en not_active IP Right Cessation
- 1989-04-19 DK DK189189A patent/DK172235B1/da not_active IP Right Cessation
- 1989-04-19 CA CA000597169A patent/CA1325976C/en not_active Expired - Lifetime
- 1989-04-19 AU AU33183/89A patent/AU3318389A/en not_active Abandoned
- 1989-04-20 JP JP1099031A patent/JP2950845B2/ja not_active Expired - Lifetime
-
1994
- 1994-12-01 HK HK134494A patent/HK134494A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK189189A (da) | 1989-10-21 |
IE62778B1 (en) | 1995-02-22 |
MC2025A1 (fr) | 1990-04-25 |
EP0338444A1 (de) | 1989-10-25 |
HK134494A (en) | 1994-12-09 |
IE891263L (en) | 1989-10-20 |
CA1325976C (en) | 1994-01-11 |
ZA892877B (en) | 1989-12-27 |
ATE97572T1 (de) | 1993-12-15 |
HUT49808A (en) | 1989-11-28 |
DK172235B1 (da) | 1998-02-02 |
EP0338444B1 (de) | 1993-11-24 |
DK189189D0 (da) | 1989-04-19 |
AU3318389A (en) | 1989-10-26 |
PT90308A (pt) | 1989-11-10 |
HU202403B (en) | 1991-03-28 |
FI891865A0 (fi) | 1989-04-19 |
FI891865A (fi) | 1989-10-21 |
JPH01311024A (ja) | 1989-12-15 |
PT90308B (pt) | 1994-10-31 |
JP2950845B2 (ja) | 1999-09-20 |
DE58906232D1 (de) | 1994-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3007202T3 (es) | ||
ES2179832T3 (es) | Formas de administracion orales con contenido en flupirtina solida, con liberacion controlada del principio activo. | |
ES2060685T3 (es) | Medicamento con contenido de azelastina con liberacion controlada del principio activo. | |
DE59102210D1 (de) | Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus. | |
ATE76747T1 (de) | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. | |
IL85523A (en) | Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it | |
ATE75945T1 (de) | Pharmazeutische zubereitung zur behandlung des diabetes mellitus. | |
ATE58292T1 (de) | L-dopa enthaltendes arzneimittel. | |
ATE173627T1 (de) | Medizinische zusammensetzung | |
ES2027773T3 (es) | Dispositivo auto-adhesivo para administracion de un principio activo por via percutanea. | |
KR830002510A (ko) | 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물 | |
ATE38151T1 (de) | Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung. | |
PH27446A (en) | Compound with gastric acid inhibitory effect | |
DE3783923D1 (de) | Einen wirkstoff und ein in wasser quellendes polymer enthaltendes arzneimittel. | |
EP0380989A3 (en) | Plaster for transdermal administration | |
HK135494A (en) | Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient | |
DE3265827D1 (en) | Pharmaceutical composition of phosphonomicin in tablet form | |
DK0560207T3 (da) | Præparat til oral anvendelse baseret på ibuprofen | |
JO1519B1 (en) | New compounds (new benzimidazole derivatives are effective as ulcers) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 338444 Country of ref document: ES |